This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
EPS for the period at Rs. (7.57)
The company reports revenue growth of 26% and PAT growth of 21% YoY
The hospital chain aggressively embarks on digitisation and is e-health ready
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
EPS at Rs 32.19
Demand normalisation post the second wave contributed to the steady growth
Income declines marginally
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
